Moderna, Inc. is a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines. The company develops a broad pipeline of mRNA medicines across multiple therapeutic areas including infectious diseases, oncology, cardiovascular disease, and rare genetic diseases. Moderna's platform enables the development of drugs that instruct cells to produce therapeutic proteins. The company's commercial products include Spikevax (COVID-19 vaccine) and Mresvia (RSV vaccine).
Moderna is publicly traded
IPO'd on December 7, 2018
This company is no longer available on our private secondary market. Shares can be traded publicly under MRNA.
Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Founded
2010
Employees
4,700
Total Funding
$2.17B
6 rounds
Last Private Valuation
$7.5B
February 2018
Total raised $2.17B across 6 rounds
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Last updated 06-25-2026
Latest Round
Type
Series G
Date
February 2018
Amount
$500M
Valuation
$7.5B
Lead Investors
| Date | Round | Amount Raised | Valuation | Lead Investors |
|---|---|---|---|---|
| February 2018 | Series G | $500M | $7.5B | Not disclosed |
| September 2016 | Series D (Merck-AZ) | $474M | — | AstraZeneca |
| August 2016 | Series E | $600M | — | Not disclosed |
Stéphane Bancel
Chief Executive Officer
Jamey Mock
Chief Financial Officer
David Berman
Chief Development Officer
Noubar Afeyan
Co-founder and Chairman
Competitor list is illustrative and may be incomplete, stale, or erroneous.
BioNTech
German biotechnology company and Moderna's primary competitor in mRNA vaccines; partnered with Pfizer for Comirnaty COVID-19 vaccine
Pfizer
Pharmaceutical company partner with BioNTech developing mRNA-based COVID-19 and other vaccines
CureVac
mRNA therapeutics company acquired by BioNTech for $1.25 billion; pioneer in mRNA-based cancer vaccines
Arcturus Therapeutics
Biotechnology company developing self-amplifying mRNA and mRNA therapeutics for various diseases
GlaxoSmithKline
Major pharmaceutical company developing mRNA therapeutics and vaccines
Yes, Moderna is publicly traded under the ticker symbol MRNA on the NASDAQ. The company went public in December 7, 2018.
Moderna trades under the ticker symbol MRNA on the NASDAQ. It began trading in December 7, 2018.
Moderna (MRNA on the NASDAQ) shares can be purchased through any standard brokerage account — including Fidelity, Charles Schwab, TD Ameritrade, and online platforms like Robinhood or E*TRADE. Search for the ticker MRNA to place an order.
Moderna went public in December 7, 2018 via ipo, with an offering valuation of approximately $7.5B. Moderna completed its initial public offering on December 7, 2018, pricing shares at $23.00 per share on the NASDAQ Global Select Market under ticker symbol MRNA. The IPO raised approximately $604.3 million and was the largest biotech IPO in history at that time.
Moderna raised $2.17B across 6 disclosed funding rounds prior to its public listing.
Moderna was founded by Noubar Afeyan in 2010.
Moderna is headquartered in Cambridge, Massachusetts, United States.
Access live market data
Sign UpData collected with AI, which can make mistakes. Please double-check this information.